Our in silico screening process followed by experimental validation revealed that a poly-ADP-ribose polymerase 1 (PARP1) inhibitor, CVL218, currently in Phase I clinical trial, may serve as a potential drug candidate to treat COVID-19. The gene discussed is PARP1; the disease is COVID-19.